Bloomberg Law Analysis

ANALYSIS: Will Suboxone Break Ground on “Product Hopping”?

Oct. 8, 2019, 10:41 AM

Direct purchasers, and some end payers, can prove their damages as a group in a challenge to a scheme to keep generic competition out of the market for the opioid treatment drug Suboxone. It’s only the third time a case of this type has reached the class certification stage.

Judge Mitchell Goldberg of the U.S. District Court for the Eastern District of Pennsylvania is presiding over the monopolization lawsuit alleging “product hopping,” a strategy employed by drugmakers to shift as many patients as possible from a drug about to see generic competition to a slightly different variant with a new...

To read the full article log in. To learn more about a subscription click here.